Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial.

BACKGROUND Mild hyponatremia is relatively common in patients hospitalized with heart failure (HF). To our knowledge, the association of hyponatremia with outcomes has not been evaluated in the context of in-hospital clinical course including central hemodynamics and changes in serum sodium level. METHODS The ESCAPE trial (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) was a randomized, controlled study designed to evaluate the utility of a pulmonary artery catheter plus clinical assessment vs clinical assessment alone in guiding therapy in patients hospitalized with New York Heart Association class IV HF due to systolic dysfunction (left ventricular ejection fraction <30%). A Cox proportional hazards model with baseline serum sodium level as a continuous variable was used to examine the association of serum sodium level with 6-month postdischarge mortality, HF rehospitalization, and death or rehospitalization. A categorical analysis was also performed comparing persistent and corrected hyponatremia. RESULTS A total of 433 hospitalized patients with HF were enrolled in ESCAPE. Hyponatremia (serum sodium level < or = 134 mEq/L) was present in 103 patients (23.8%). (To convert serum sodium to millimoles per liter, multiply by 1.0.) Of these, 71 had persistent hyponatremia (68.9%). Hyponatremia was associated with higher 6-month mortality after covariate adjustment (hazard ratio [HR] for each 3-mEq/L decrease in sodium level, 1.23; 95% confidence interval [CI], 1.05-1.43) (P = .01). After controlling for baseline variables and clinical response, we found that patients with persistent hyponatremia had an increased risk of all-cause mortality (31% vs 16%; HR, 1.82) (P = .04), HF rehospitalization (62% vs 43%; HR, 1.52) (P = .03), and death or rehospitalization (73% vs 50%; HR, 1.54) (P = .01) compared with normonatremic patients. CONCLUSION Persistent hyponatremia was an independent predictor of mortality, HF hospitalization, and death or rehospitalization despite clinical and hemodynamic improvements that were similar to those in patients without hyponatremia.

[1]  J. Cohn,et al.  Neurohumoral control mechanisms in congestive heart failure. , 1981, American heart journal.

[2]  T. Berl,et al.  Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. , 2006, The New England journal of medicine.

[3]  G. Fonarow,et al.  Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. , 2007, European heart journal.

[4]  D. DeMets,et al.  Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). , 2005, Journal of cardiac failure.

[5]  David D. Shin,et al.  Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial , 2007, Acute cardiac care.

[6]  Christopher M O'Connor,et al.  Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. , 2004, JAMA.

[7]  V. Dzau Renal and circulatory mechanisms in congestive heart failure. , 1987, Kidney international.

[8]  M. Gheorghiade,et al.  Vasopressin V2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure: Results From a Double-Blind, Randomized Trial , 2003, Circulation.

[9]  E. Braunwald,et al.  CATECHOLAMINE EXCRETION AND CARDIAC STORES OF NOREPINEPHRINE IN CONGESTIVE HEART FAILURE. , 1965, The American journal of medicine.

[10]  R. Califf,et al.  Lower Serum Sodium Is Associated With Increased Short-Term Mortality in Hospitalized Patients With Worsening Heart Failure: Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Study , 2005, Circulation.

[11]  T. Berl,et al.  Osmotic and nonosmotic control of vasopressin release. , 1979, The American journal of physiology.

[12]  N. Hollenberg,et al.  Hyponatremia in congestive heart failure: implications for neurohumoral activation and responses to orthostasis. , 1984, The Journal of clinical endocrinology and metabolism.

[13]  W. Abraham,et al.  Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.

[14]  M. Gheorghiade,et al.  Vasopressin V 2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure Results From a Double-Blind , Randomized Trial , 2003 .

[15]  William T. Abraham,et al.  Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness , 2005 .

[16]  W. Frishman,et al.  Systolic Blood Pressure at Admission, Clinical Characteristics, and Outcomes in Patients Hospitalized With Acute Heart Failure , 2007 .

[17]  V. Hasselblad,et al.  Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. , 2004, Journal of the American College of Cardiology.

[18]  A. Greenberg,et al.  Diuretic complications. , 2000, The American journal of the medical sciences.

[19]  V. Hasselblad,et al.  Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): design and rationale. , 2001, American heart journal.

[20]  William T. Abraham,et al.  Risk stratification for in-hospital mortality in acutely decompensated heart failure. Classification and regression tree analysis , 2005 .

[21]  K. Swedberg,et al.  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.

[22]  L. Tavazzi,et al.  Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry). , 2002, American heart journal.

[23]  J. Cohn,et al.  Hyponatraemia as a marker for high renin heart failure. , 1982, British heart journal.

[24]  K. Swedberg,et al.  Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. , 2007, JAMA.

[25]  M. Packer,et al.  Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia. , 1984, The New England journal of medicine.

[26]  Monica R. Shah,et al.  Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness The ESCAPE Trial , 2005 .

[27]  N. Hollenberg,et al.  Relation of the Renin‐Angiotensin-Aldosterone System to Clinical State in Congestive Heart Failure , 1981, Circulation.